An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies

Trial Profile

An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Lonafarnib (Primary) ; Pravastatin; Zoledronic acid
  • Indications Progeria
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 18 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 14 Apr 2017 Planned number of patients changed from 45 to 85.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top